Gilead Sciences Inc(GILD)

62.10

Change: 0 (0)

As of Wed 09/30/2020 03:01 AM

% Of Value

Growth

Value Per Share

:

:

:

134.39

-15.24

46.2100

Fundamentals Data

Open 67.80 Dividend 1358
Close Price 62.10 DivYield 2.42 %
High 67.83 Growth -3,980,000,000.00
Low 66.66 Growth% -15.24
P/e 15.28 Volume 358,929,516.00
P/b 11.39 Market Capital 83,354,614,965
Highest High 85.47 Lowest Low 64.12
50 Days Moving Average 65.95 50 Days Moving Average Percentage 70.80
Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Balance Sheet Table: last 5 years

Note: Numbers are estimated, Exact figures can be found in Annual Reports
Type Year1 / 2014 Year2 / 2015 Year3 / 2016 Year4 / 2017 Current Year / 2018
Revenue 24,890,000,000 32,639,000,000 30,390,000,000 26,107,000,000 22,127,000,000
Cap Spending -557,000,000 -747,000,000 -748,000,000 -590,000,000 -924,000,000
Operating Expenses 5,837,000,000 6,440,000,000 8,496,000,000 7,612,000,000 9,074,000,000
Operating Cash Flow 15,265,000,000 22,193,000,000 17,633,000,000 14,124,000,000 8,200,000,000
Free Cash Flow 12,261,000,000 19,582,000,000 15,921,000,000 11,308,000,000 7,476,000,000
Free Cash Flow Per Share 8.056 13.376 11.89 8.652 5.76
Total liabilities 12,404,000,000 22,178,000,000 26,346,000,000 33,542,000,000 27,322,000,000
Total cash 10,027,000,000 12,851,000,000 8,229,000,000 7,588,000,000 17,940,000,000
ROE% 0.828 1.043 0.835 0.209 0.252
Outstanding Shares 1,489,401,683 1,366,845,691 1,307,066,900 1,309,967,781 1,275,510,558
P/E 12.853 6.745 6.825 22.746 15.28
P/S 6.249 3.742 3.032 4.032 3.767
Revenue USD 24,890,000,000 32,639,000,000 30,390,000,000 26,107,000,000 22,127,000,000

Reports for GILD

Date Author Title Action
2020-09-08 stanko Gilead Sciences equity, debt and subsidiaries view
2016-10-13 stanko gilead is the leader of hep C drugs and 14 brand names with 1/3 of market cap in debt view

Latest Searches

Stock Close Price %of value Date